DE2443492A1 - Mittel zur behandlung der atmungswege - Google Patents
Mittel zur behandlung der atmungswegeInfo
- Publication number
- DE2443492A1 DE2443492A1 DE2443492A DE2443492A DE2443492A1 DE 2443492 A1 DE2443492 A1 DE 2443492A1 DE 2443492 A DE2443492 A DE 2443492A DE 2443492 A DE2443492 A DE 2443492A DE 2443492 A1 DE2443492 A1 DE 2443492A1
- Authority
- DE
- Germany
- Prior art keywords
- mercaptopropionylglycine
- respiratory
- day
- well
- alkali salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000241 respiratory effect Effects 0.000 title description 2
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 claims description 31
- 108010058907 Tiopronin Proteins 0.000 claims description 31
- 150000001447 alkali salts Chemical class 0.000 claims description 14
- 159000000000 sodium salts Chemical class 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 210000004400 mucous membrane Anatomy 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 230000000510 mucolytic effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 description 10
- 210000003097 mucus Anatomy 0.000 description 10
- 239000006188 syrup Substances 0.000 description 9
- 235000020357 syrup Nutrition 0.000 description 9
- 206010006458 Bronchitis chronic Diseases 0.000 description 7
- 206010036790 Productive cough Diseases 0.000 description 7
- 208000007451 chronic bronchitis Diseases 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 6
- 201000004193 respiratory failure Diseases 0.000 description 6
- 229940008126 aerosol Drugs 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 206010014561 Emphysema Diseases 0.000 description 4
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- SXZQVFPZKHBROS-UHFFFAOYSA-N 2-(2-benzylsulfanylpropanoylamino)acetic acid Chemical compound C(C1=CC=CC=C1)SC(C(=O)NCC(=O)O)C SXZQVFPZKHBROS-UHFFFAOYSA-N 0.000 description 1
- QKHQITUHYKZKJI-UHFFFAOYSA-N 2-benzylsulfanylpropanoic acid Chemical compound OC(=O)C(C)SCC1=CC=CC=C1 QKHQITUHYKZKJI-UHFFFAOYSA-N 0.000 description 1
- DJDJOEJUIYVBLI-UHFFFAOYSA-N 2-methyl-3-phenyl-2-sulfanylpropanoic acid Chemical compound OC(=O)C(S)(C)CC1=CC=CC=C1 DJDJOEJUIYVBLI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- YZPDDJFVLZMXNL-UHFFFAOYSA-N CC(CC1=CC=CC=C1)(C(Cl)=O)S Chemical compound CC(CC1=CC=CC=C1)(C(Cl)=O)S YZPDDJFVLZMXNL-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010009126 Chronic respiratory failure Diseases 0.000 description 1
- 206010012435 Dermatitis and eczema Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US00397865A US3857951A (en) | 1973-09-14 | 1973-09-14 | Use of 2-mercaptopropionylglycine and its alkali metal salts in treating respiratory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2443492A1 true DE2443492A1 (de) | 1975-03-27 |
| DE2443492C2 DE2443492C2 (en:Method) | 1987-06-11 |
Family
ID=23572987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2443492A Granted DE2443492A1 (de) | 1973-09-14 | 1974-09-11 | Mittel zur behandlung der atmungswege |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US3857951A (en:Method) |
| BE (1) | BE819823A (en:Method) |
| CA (1) | CA1026233A (en:Method) |
| DE (1) | DE2443492A1 (en:Method) |
| GB (1) | GB1482651A (en:Method) |
| ZA (1) | ZA745219B (en:Method) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4140786A (en) * | 1976-05-10 | 1979-02-20 | E. R. Squibb & Sons, Inc. | Method for alleviating angiotensin related hypertension |
| US4053651A (en) * | 1976-05-10 | 1977-10-11 | E. R. Squibb & Sons, Inc. | Compounds and method for alleviating angiotensin related hypertension |
| US4199512A (en) * | 1976-05-10 | 1980-04-22 | E. R. Squibb & Sons, Inc. | Compounds for alleviating hypertension |
| US4113715A (en) * | 1977-01-17 | 1978-09-12 | E. R. Squibb & Sons, Inc. | Amino acid derivatives |
| US4093739A (en) * | 1977-06-15 | 1978-06-06 | Mead Johnson & Company | Mercaptoacylamidobenzoyl glycine and mucolytic process |
| IT1098328B (it) * | 1978-06-16 | 1985-09-07 | Gargani Pietro | Sale sodico della mercapropropionilglicina,processo per la sua preparazione e suoi impieghi terapeutici |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1491204A (fr) * | 1962-08-10 | 1967-08-11 | Santen Pharmaceutical Co Ltd | Procédés pour la préparation des alpha-et beta mercaptopropionylglycocolle et de leurs dérivés |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR226M (fr) * | 1960-08-19 | 1961-02-27 | Rech S Et Propagande Scient | Médicament soufré, utilisable en particulier en oto-rhino-laryngologie et en pneumologie. |
| GB1114313A (en) * | 1964-11-19 | 1968-05-22 | Wyeth John & Brother Ltd | Pharmaceutical compositions |
-
1973
- 1973-09-14 US US00397865A patent/US3857951A/en not_active Expired - Lifetime
-
1974
- 1974-08-14 ZA ZA00745219A patent/ZA745219B/xx unknown
- 1974-09-11 DE DE2443492A patent/DE2443492A1/de active Granted
- 1974-09-12 BE BE148442A patent/BE819823A/xx not_active IP Right Cessation
- 1974-09-13 CA CA209,355A patent/CA1026233A/en not_active Expired
- 1974-09-16 GB GB40312/74A patent/GB1482651A/en not_active Expired
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1491204A (fr) * | 1962-08-10 | 1967-08-11 | Santen Pharmaceutical Co Ltd | Procédés pour la préparation des alpha-et beta mercaptopropionylglycocolle et de leurs dérivés |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2443492C2 (en:Method) | 1987-06-11 |
| BE819823A (fr) | 1975-03-12 |
| AU7139474A (en) | 1976-01-22 |
| US3857951A (en) | 1974-12-31 |
| GB1482651A (en) | 1977-08-10 |
| ZA745219B (en) | 1975-09-24 |
| CA1026233A (en) | 1978-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3587928T2 (de) | N-Acetylneuraminsäure und deren Salze enthaltende Expektorantien. | |
| DE2913211C2 (de) | 2-(2-Thenoylthio)-propionylglycin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Mittel | |
| DE10334820B4 (de) | Pharmazeutische Zusammensetzungen mit antibiotischer Aktivität | |
| DE3000743C2 (de) | Arzneipräparat auf der Basis eines Salzes der Acetylsalicylsäure und einer basischen Aminosäure | |
| DE2443492A1 (de) | Mittel zur behandlung der atmungswege | |
| DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
| DE2504331A1 (de) | Heptaminol-5'-adenosinmonophosphat und dessen therapeutische verwendung | |
| DE1620629C3 (de) | Verwendung eines Salzes von 2-Merkaptoäthansulf onsäure zur Herstellung von Mukolytica | |
| DE3212909C2 (en:Method) | ||
| AT396332B (de) | Pharmazeutische zusammensetzung | |
| DE1768655A1 (de) | Neue Salze der N-Carbamylglutaminsaeure und der N-Carbamylasparaginsaeure | |
| DE2635293A1 (de) | Salzgemisch, insbesondere leicht assimilierbares arzneimittelgemisch mit erhoehter loeslichkeit, enthaltend kalziumsalze und/oder magnesiumsalze | |
| DE1043587B (de) | Verfahren zur Herstellung eines Appetitzueglers | |
| DE3780702T2 (de) | Verwendung von etodolac zur senkung des blutgehalts an harnsaeure. | |
| DE69426317T2 (de) | Verwendung von Beta-Naphthochinonderivaten zur Hemmung von Blutplättchen-Aggregation | |
| DE69904051T2 (de) | Zubereitung enthaltend derivate von phenylaminothiophenessigsäure zur behandlung der akuten respiratorischen insuffizienz (ards) und der akuten respiratorischen insuffizienz bei kindern (irds) | |
| DE2916880C2 (de) | Arzneimittel mit sedativer und schlafinduzierender Wirkung | |
| DE68905392T2 (de) | Penizillinpraeparat zur rektalen verabreichung. | |
| DE2245826C3 (de) | Salze von N-Cyano-äthyl-N'-m-chlorphenyl-piperazin | |
| DE69200794T2 (de) | Verwendung von 4,9,11-Trien-Steroiden in Zusammensetzungen für Truthühner. | |
| DE2305271A1 (de) | Kristallines ammonium-n-acetyl-lcysteinat und verfahren zu dessen herstellung | |
| DE862341C (de) | Verfahren zur Herstellung von waessrigen Loesungen von Derivaten des p-Aminobenzolsulfonamids | |
| DE2111557C3 (de) | 1 -(3-SuIfamoyl-4-chlor-benzamido) -3-(2-furyl)-pyrrolidin und ein Verfahren zu dessen Herstellung | |
| DE1695781C3 (de) | Psychotropes Arzneimittel | |
| DE833103C (de) | Verfahren zur Herstellung eines Gichtmittels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8128 | New person/name/address of the agent |
Representative=s name: ZUMSTEIN SEN., F., DR. ASSMANN, E., DIPL.-CHEM. DR |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |